Zanubrutinib + R-BAC

Zanubrutinib + R-BAC is a combination therapy regimen that includes zanubrutinib (a BTK inhibitor) combined with R-BAC. Based on the search results, R-BAC likely refers to rituximab plus a chemotherapy combination. The specific chemotherapy components of R-BAC are not fully detailed in the provided information. Zanubrutinib (brand name Brukinsa) is a next-generation, highly selective Bruton's tyrosine kinase (BTK) inhibitor used in various B-cell malignancies. It is being studied in combination with anti-CD20 antibodies (like rituximab and obinutuzumab) and chemotherapy regimens. Zanubrutinib is FDA-approved in combination with obinutuzumab for relapsed or refractory follicular lymphoma (based on the ROSEWOOD trial). The standard dosing for zanubrutinib is typically 160 mg twice daily or 320 mg once daily. While the specific zanubrutinib + R-BAC combination isn't detailed with specific trial information in the provided text, zanubrutinib is being studied in various other combinations for different B-cell lymphomas.

Brand names

Brukinsa + R-BAC

Other names

Zanubrutinib plus R-BACZanubrutinib-RBAC